Rexgenero Shortlisted as a Finalist for Clinical Trial of the Year Lifestars Award
Rexgenero, a clinical-stage regenerative medicine company pioneering the development of advanced cell-based therapies, has been shortlisted as a finalist for the Clinical Trial of the Year Lifestars Award.
The annual European Lifestars Awards, organised by LSX, the influential community of senior life science decision makers, bring together hundreds of European life science leaders, investors, partners and deal makers, to celebrate the success stories, breakthroughs, transactions and transformational deals and the people, teams and organisations that have played a critical role in the advancement of the industry over the previous 12 months.
The Clinical Trial of the Year category recognises a European life science company that has realised a significant milestone in the clinic for a new therapy, drug, diagnostic tool, digital application or medical device.
Rexgenero has been shortlisted on the basis of their pivotal, placebo-controlled, double-blind and adaptive Phase III SALAMANDER clinical trial for chronic-limb threatening ischemia. The trial will test the efficacy and safety of Rexgenero’s cell therapy candidate, REX-001, in patients with Rutherford Category 5 chronic limb-threatening ischemia and ischemic ulcers.
The winner will be announced at the LSX Lifestars Awards Ceremony, London, UK, 19th November.